Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M108 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Beijing Mingzhi Zhishan Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
M108 + chemotherapy is a combination therapy consisting of the monoclonal antibody **FG-M108 (M108)** and standard chemotherapy regimens such as CAPOX (capecitabine plus oxaliplatin) or AG (nab-paclitaxel plus gemcitabine)[1][2][4]. FG-M108 is a human monoclonal antibody that targets **Claudin 18.2 (CLDN18.2)**, a cell surface protein selectively expressed in certain gastrointestinal cancers, most notably advanced gastric/gastroesophageal junction adenocarcinoma and pancreatic cancer. By binding CLDN18.2, FG-M108 mediates cancer cell death via enhanced antibody-dependent cellular cytotoxicity (ADCC)[1][2][4]. The combination is under clinical investigation as a first-line treatment for patients with tumors expressing CLDN18.2 and HER2-negative status.
- Other names
- FG-M108 + chemotherapy
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on M108 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M108 + chemotherapy.